-
Signature
-
/s/ Louisa Daniels, Attorney-in-Fact for Xingjuan (Jane) Chao
-
Issuer symbol
-
CBLL
-
Transactions as of
-
17 Apr 2025
-
Net transactions value
-
+$20,321
-
Form type
-
4/A - Amendment
-
Filing time
-
12 Sep 2025, 12:32:29 UTC
-
Date Of Original Report
-
21 Apr 2025
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Chao Xingjuan |
President and CEO, Director |
C/O CERIBELL, INC., 360 N. PASTORIA AVENUE, SUNNYVALE |
/s/ Louisa Daniels, Attorney-in-Fact for Xingjuan (Jane) Chao |
12 Sep 2025 |
0002035784 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
CBLL |
Common Stock |
Options Exercise |
$12,768 |
+5,700 |
+0.76% |
$2.24 |
757,851 |
17 Apr 2025 |
Direct |
F1, F2 |
| transaction |
CBLL |
Common Stock |
Options Exercise |
$7,553 |
+3,372 |
+0.44% |
$2.24 |
761,223 |
21 Apr 2025 |
Direct |
F1, F2 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
| transaction |
CBLL |
Stock Option (Right to Buy) |
Options Exercise |
$0 |
-5,700 |
-3.7% |
$0.000000 |
146,851 |
17 Apr 2025 |
Common Stock |
5,700 |
$2.24 |
Direct |
F1, F2, F3 |
| transaction |
CBLL |
Stock Option (Right to Buy) |
Options Exercise |
$0 |
-3,372 |
-2.3% |
$0.000000 |
143,479 |
21 Apr 2025 |
Common Stock |
3,372 |
$2.24 |
Direct |
F1, F2, F3 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: